
Please try another search
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Name | Age | Since | Title |
---|---|---|---|
Gwill York | 67 | 2021 | Independent Director |
Amit Etkin | 48 | 2019 | Founder, Chairman of the Board, CEO & President |
Dan Segal | 63 | 2019 | Co-Founder & Strategic Advisor |
Christopher Nixon Cox | 45 | 2022 | Lead Independent Director |
Husseini K. Manji | 66 | 2024 | Non-Employee Independent Director |
Thomas R. Insel | 72 | - | Scientific Advisor |
Alan F. Schatzberg | 80 | - | Scientific Advisor |
Quentin Huys | - | - | Scientific Advisor |
Andrew C. Dreyfus | 66 | 2023 | Independent Director |
Madhukar H. Trivedi | - | - | Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review